Federal Circuit Affirms Cladribine Patent Invalidity in Merck Serono v. Hopewell Pharma in Key MS Drug Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Merck Serono, SA v. Hopewell Pharma Ventures, Inc. |
| Case Number | 25-1211 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Nov 2024 – Oct 2025 11 months |
| Outcome | Defendant Win – Patent Invalidated |
| Patents at Issue | |
| Accused Product/Method | Cladribine regimen for treating multiple sclerosis |
Case Overview
The Parties
⚖️ Plaintiff
The biopharmaceutical arm of Merck KGaA, global leader in specialty therapeutics including multiple sclerosis treatments. Markets Mavenclad®.
🛡️ Defendant/Challenger
Pharmaceutical company focused on generic and specialty drug development, challenging branded pharmaceutical IP.
The Patent at Issue
This case involved U.S. Patent No. 8,377,903 B2, covering a specific cladribine treatment regimen for treating relapsing-remitting multiple sclerosis. It was central to Merck Serono’s Mavenclad® exclusivity.
- • US 8,377,903 B2 — Dosing regimen of cladribine for treating MS
- • **Technology Area** — Pharmaceutical method patents, specifically dosing regimen of cladribine
- • **Core Claims** — Specific dosing schedules and cumulative dose parameters for therapeutic efficacy with managed side effects
Developing a new MS drug?
Check if your cladribine regimen might infringe related patents or benefit from this ruling.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clean **AFFIRMED** judgment, upholding the lower tribunal’s finding that **U.S. Patent No. 8,377,903 B2 is unpatentable**. The basis of termination is recorded as “Unpatentable” — confirming cancellation of the asserted claims. No damages award or injunctive relief was at issue, consistent with an invalidity/cancellation proceeding.
Key Legal Issues
The verdict cause is classified as **Patentability — Invalidity/Cancellation Action**, meaning Hopewell Pharma successfully challenged whether the ‘903 patent’s claims met the statutory requirements for patentability. Common grounds for such challenges include obviousness (§ 103) where prior art disclosed cladribine’s use in MS, or lack of written description/enablement (§ 112).
The Federal Circuit’s affirmance signals that the lower tribunal’s patentability analysis withstood appellate scrutiny on both the factual and legal determinations, reinforcing the **substantial evidence** standard applied to PTAB fact-findings.
This decision carries **precedential weight** for pharmaceutical method patent practitioners. Treatment regimen patents, often filed as secondary patents, face sustained invalidity risk when prior art establishes the underlying compound’s therapeutic utility. It also reinforces the court’s established practice of deferring to PTAB factual findings.
Filing a pharmaceutical method patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical dosing regimens. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for MS drug development.
- View related cladribine or MS treatment patents
- See which pharma companies are most active in MS IP
- Understand method claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your drug regimen description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Pharmaceutical dosing regimens
1 Patent Cancelled
US 8,377,903 B2 now unpatentable
FTO Re-assessment Needed
For cladribine-based MS therapies
✅ Key Takeaways
For Patent Attorneys & Litigators
The Federal Circuit’s affirmance reinforces broad PTAB deference on factual patentability determinations.
Search related case law →Pharmaceutical method claims covering dosing regimens require carefully differentiated prosecution records.
Explore precedents →For R&D Teams & IP Professionals
FTO analyses for cladribine-based MS therapies must now account for the cancelled status of the ‘903 patent.
Start FTO analysis for my product →Treatment regimen patents offer less durable exclusivity than previously assumed; factor this into IP strategy.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.